Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Further insights into the SAR of α-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A.

Authors:
Marco Pieroni Giannamaria Annunziato Elisa Azzali Paola Dessanti Ciro Mercurio Giuseppe Meroni Paolo Trifiró Paola Vianello Manuela Villa Claudia Beato Mario Varasi Gabriele Costantino

Eur J Med Chem 2015 Mar 7;92:377-86. Epub 2015 Jan 7.

Dipartimento Farmaceutico, University of Parma, Parco Area delle Scienze 27/A, Parma 43124, Italy. Electronic address:

Epigenetics alterations including histone methylation and acetylation, and DNA methylation, are thought to play important roles in the onset and progression of cancer in numerous tumour cell lines. Lysine-specific demethylase 1 (LSD1 or KDM1A) is highly expressed in different cancer types and inhibiting KDM1A activity seems to have high therapeutic potential in cancer treatment. In the recent years, several inhibitors of KDM1A have been prepared and disclosed. The majority of these derivatives were designed based on the structure of tranylcypromine, as the cyclopropane core is responsible for the covalent interaction between the inhibitor and the catalytic domain of KDM proteins. In this study, we have further extended the SAR regarding compounds 1a-e, which were recently found to inhibit KDM1A with good activity. The decoration of the phenyl ring at the β-position of the cyclopropane ring with small functional groups, mostly halogenated, and in particular at the meta position, led to a significant improvement of the inhibitory activity against KDM1A, as exemplified by compound 44a, which has a potency in the low nanomolar range (31 nM).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2014.12.032DOI Listing
March 2015

Publication Analysis

Top Keywords

kdm1a
6
therapeutic potential
4
meta position
4
high therapeutic
4
activity high
4
activity decoration
4
potential cancer
4
proteins study
4
inhibitors kdm1a
4
years inhibitors
4
treatment years
4
halogenated meta
4
cancer treatment
4
position led
4
study extended
4
highly expressed
4
kdm1a highly
4
improvement inhibitory
4
lsd1 kdm1a
4
expressed cancer
4

Altmetric Statistics


Show full details
4 Total Shares
1 Tweets
4 Citations

Similar Publications

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.

Authors:
Xing-Jie Dai Ying Liu Lei-Peng Xue Xiao-Peng Xiong Ying Zhou Yi-Chao Zheng Hong-Min Liu

J Med Chem 2021 Feb 23. Epub 2021 Feb 23.

Key Lab of Advanced Drug Preparation Technologies, Ministry of Education of China, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China.

As a flavin adenine dinucleotide (FAD)-dependent monoamine oxidase, lysine specific demethylase 1 (LSD1/KDM1A) functions as a transcription coactivator or corepressor to regulate the methylation of histone 3 lysine 4 and 9 (H3K4/9), and it has emerged as a promising epigenetic target for anticancer treatment. To date, numerous inhibitors targeting LSD1 have been developed, some of which are undergoing clinical trials for cancer therapy. Although only two reversible LSD1 inhibitors CC-90011 and SP-2577 are in the clinical stage, the past decade has seen remarkable advances in the development of reversible LSD1 inhibitors. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Annual review of LSD1/KDM1A inhibitors in 2020.

Authors:
Dong-Jun Fu Jun Li Bin Yu

Eur J Med Chem 2021 Feb 3;214:113254. Epub 2021 Feb 3.

School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou, 450001, China. Electronic address:

Lysine-specific demethylase 1 (LSD1/KDM1A) has emerged as a promising target for the discovery of specific inhibitors as antitumor drugs. Based on the source of compounds, all LSD1 inhibitors in this review are divided into two categories: natural LSD1 inhibitors and synthetic LSD1 inhibitors. This review highlights the research progress of LSD1 inhibitors with the potential to treat cancer covering articles published in 2020. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.

Authors:
Maria Teresa Borrello Hanae Benelkebir Adam Lee Chak Hin Tam Manar Shafat Stuart A Rushworth Kristian M Bowles Leon Douglas Patrick J Duriez Sarah Bailey Simon J Crabb Graham Packham A Ganesan

ChemMedChem 2021 Feb 3. Epub 2021 Feb 3.

School of Pharmacy, University of East Anglia, Norwich, NR4 7TJ, UK.

Lysine-specific demethylase 1 (LSD1/KDM1A) oxidatively removes methyl groups from histone proteins, and its aberrant activity has been correlated with cancers including acute myeloid leukemia (AML). We report a novel series of tranylcypromine analogues with a carboxamide at the 4-position of the aryl ring. These compounds, such as 5 a and 5 b with benzyl and phenethylamide substituents, respectively, had potent sub-micromolar IC values for the inhibition of LSD1 as well as cell proliferation in a panel of AML cell lines. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

LSD1 is an environmental stress-sensitive negative modulator of the glutamatergic synapse.

Authors:
A Longaretti C Forastieri E Toffolo L Caffino A Locarno I Misevičiūtė E Marchesi M Battistin L Ponzoni L Madaschi C Cambria M P Bonasoni M Sala D Perrone F Fumagalli S Bassani F Antonucci R Tonini M Francolini E Battaglioli F Rusconi

Neurobiol Stress 2020 Nov 27;13:100280. Epub 2020 Nov 27.

Dept. of Medical Biotechnology and Translational Medicine, Università Degli Studi di Milano, Via F.lli Cervi, 93, Segrate (MI), Italy.

Along with neuronal mechanisms devoted to memory consolidation -including long term potentiation of synaptic strength as prominent electrophysiological correlate, and inherent dendritic spines stabilization as structural counterpart- negative control of memory formation and synaptic plasticity has been described at the molecular and behavioral level. Within this work, we report a role for the epigenetic corepressor Lysine Specific Demethylase 1 (LSD1) as a negative neuroplastic factor whose stress-enhanced activity may participate in coping with adverse experiences. Constitutively increasing LSD1 activity via knocking out its dominant negative splicing isoform neuroLSD1 (neuroLSD1 mice), we observed extensive structural, functional and behavioral signs of excitatory decay, including disrupted memory consolidation. Read More

View Article and Full-Text PDF
November 2020
Similar Publications

Pilocarpine-induced seizures associate with modifications of LSD1/CoREST/HDAC1/2 epigenetic complex and repressive chromatin in mice hippocampus.

Authors:
Verónica Noches Carlos Rivera Marcela P González Gianluca Merello Montserrat Olivares-Costa María Estela Andrés

Biochem Biophys Rep 2021 Mar 29;25:100889. Epub 2020 Dec 29.

Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.

Epilepsy is a neurological disorder of genetic or environmental origin characterized by recurrent spontaneous seizures. A rodent model of temporal lobe epilepsy is induced by a single administration of pilocarpine, a non-selective cholinergic muscarinic receptor agonist. The molecular changes associated with pilocarpine-induced seizures are still poorly described. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap